Presidio Pharmaceuticals and Numerate Announce Research Collaboration to Identify Improved Hepatitis C Therapeutics
News Feb 12, 2008
Presidio Pharmaceuticals, Inc. and Numerate, Inc. announced that they have entered into a research collaboration to discover and develop novel small molecule inhibitors of hepatitis C virus (HCV). Terms of the collaboration and the specific HCV target were not disclosed.
“I am very pleased to have entered into this agreement,” stated Dr. Richard Colonno, Chief Scientific Officer of Presidio Pharmaceuticals.
“Numerate has a very promising computational approach that we believe will help expand our HCV portfolio in a highly competitive area encumbered by many patents. Numerate’s drug engineering process addresses the key design criteria in parallel with a focus on delivering advanced lead compounds quickly. The process accelerates the discovery and design of novel leads and reduces the time and cost needed to advance compounds into clinical trials.”
“We look forward to working with Presidio to deliver proprietary, potent, and selective small molecule leads, enabling them to rapidly identify clinical development candidates,” stated Guido Lanza, Chief Executive Officer of Numerate. “We anticipate a true synergistic working relationship with Presidio, working directly with their scientific team to provide lead and backup molecules for the HCV collaboration.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE